Company profilePharmaceutical#209 of 1,318 in Pakistan4 DRAP alerts

M/s. Zafa Pharmaceutical Laboratories (Pvt) Ltd

Pharmaceutical company · 87 brands · 60 molecules

Ranked #79 of 213 companies in Other Beta-Lactam, Cephalosporins & Penems

87 registered products 49 pharmaceutical brands 60 distinct molecules 4 DRAP alerts

Company overview

87
registered products
49
pharmaceutical brands
60
distinct molecules
8
therapeutic classes
4
DRAP alerts

M/s. Zafa Pharmaceutical Laboratories (Pvt) Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 87 product registrations across 60 distinct molecules. Its portfolio is concentrated in Other Beta-Lactam, Cephalosporins & Penems and Solutions Producing Osmotic Diuresis. DRAP has issued 4 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by M/s.

5 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

4
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20264

Top molecules by brand count

Amoxicillin13 brands
Rifampicin5 brands
Glucose / Glucose ...... 50.0/3 brands
Ibuprofen3 brands
Penicillin-G Benzathine ...... 0.6 Mu2 brands

Therapeutic classes

Other Beta-Lactam, Cephalosporins & Penems · 4Solutions Producing Osmotic Diuresis · 1Hormonal Contraceptives, Systemic · 1Hormone Regulators · 1Gonadotropins And Other Ovulation Stimulants · 1Anti-Infectives · 1Beta-Lactamase Sensitive Penicillins · 1Antiinflammatory And Antirheumatic Products · 1

Conditions treated

Hormonal Therapy · 1Contraceptives · 1General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official100 products · Rs 30.79 – Rs 9,045.85
DVAGO1 products · Rs 149.86 – Rs 149.86
Servaid4 products · Rs 46.87 – Rs 125.58
Median across source: Rs 149.86

Regulatory record

4 alerts in the DRAP feed we track.

RECALL ALERT – FAMILA 28F TABLETS (Batch # K159, K196, K197, K198) DECLARED SUBSTANDARD.
2025-09-10
RECALL ALERT – DRUG PRODUCTS DECLARED SUBSTANDARD BY CENTRAL DRUGS LABORATORY, KARACHI.
2025-08-18
RECALL ALERT – BATCHES OF ‘TABLET FAMILA 28F’ DECLARED SUBSTANDARD BY CENTRAL DRUGS LABORA
2025-08-04
Recall Alert: Drug Product; Famila 150mg Injection (Batch # 083) By Zafa Pharmaceutical La
2024-10-25

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

AGP (PRIVATE) LTD. holds 142 molecules not in this portfolio
AmikacinAminophyllineAmlodipineAprepitantArtemetherAtorvastatin
Wilshire Laboratories (Private) Limited holds 132 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxycillinAmoxycillin Base
MEDIATE PHARMACEUTICALS (PVT) LTD holds 113 molecules not in this portfolio
AcyclovirAlendronateAmlodipineAmpicillinAmpicillin BaseAnastrozole

Get the full profile for M/s.

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.